65,437 trials
Cardiovascular Diseases · Adherence, Medication · Medication Adherence
Primary: Medication Adherence — .606; .620; .623; .630 mean PDC — p=<0.05
Ischemic Stroke
Primary: Good Functional Recovery — 84; 68 patients — p=<0.01
Primary Orthostatic Tremor
Primary: Change in Fullerton Advanced Balance (FAB) Scale Total Score After rTMS — 2.8; 0.9 change in score on a scale
Infertility
Primary: Number of Oocytes Retrieved — 9.0; 9.0 Oocytes Retrieved
Massive Pulmonary Embolism
Primary: Death From All Causes — 3; 4 Participants — p=<0.05
Systemic Sclerosis · Fatigue · Raynaud Phenomenon
Primary: Change in PROMIS® Item Bank v1.0 - Fatigue - Short Form 13a (FACIT-Fatigue) at 4 Weeks (End-of-Study) Compared to Baseline — -7.0; 62.5 T-score — p=<0.001
Long COVID
Primary: Change in Functional Improvement Post-COVID-19 Over Time — 8.4; 21.05; 4.55; 6.6 score on a scale — p=.06
Respiratory Syncytial Viruses · Respiratory Syncytial Virus Infections
Primary: Adjusted Geometric Mean Concentration (GMC) of Anti-glycoprotein E (gE) Antibodies at 1 Month Post-second Dose of HZ/su Vaccination — 49326.9; 61192.7 mIU/mL
Stroke
Primary: Relative Contribution (RC) — -0.74; -0.25 percent
Chronic Pain
Primary: Feasibility Will be Assessed by the Percent of Participants Who Complete — 6 Participants
Family Reported Errors and Adverse Events
Primary: Family Safety Reporting Rates — 61; 60 Participants
Depression · Depressive Symptoms · Cancer
Primary: Accrual — 10; 20 Participants
Tobacco Use Disorder
Primary: Cigarettes Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Non Small Cell Lung Cancer Metastatic
Primary: Time to Best Overall Response — 14 months
Schizophrenia
Primary: Negative Symptom Assessment-16 (NSA-16) Total Score - Change From Baseline to Week 26 — -12.14; -11.09 score on a scale — p=0.4825